Merck joins forces with UK cancer research organizations

17 January 2018

Cancer Research UK’s Commercial Partnerships Team and The Institute of Cancer Research, London, today announced a multi-project collaboration and licensing deal with Germany’s Merck KGaA (MRK: DE), to discover and develop new anticancer drugs.

This multi-project deal follows previous single project drug discovery collaborations and a more recent target validation collaboration between Merck and Cancer Research UK’s Cancer Therapeutics Unit at The Institute of Cancer Research (ICR).

The parties will collaborate on three independent research projects spanning target hit discovery to preclinical candidate nomination. This work will progress the discovery and development of potential cancer drugs, as well as develop biomarkers for target engagement and patient selection.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK